All In Biotech

Drug Trial Radar · NCT02657330

Study of SBP-101 in Pancreatic Cancer

A Phase 1A/1B Study of SBP-101 in Previously Treated Subjects With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Apr 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Jan 2016

Primary completion

Oct 2017

Study completion Oct 2017

Sponsor

Lead sponsor
Panbela Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101.

Conditions

  • Pancreatic Cancer
  • Ductal Adenocarcinoma of the Pancreas

Interventions

  • SBP-101Drug

    Subcutaneous drug, escalating dose cohorts

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose of SBP-101Time frame: Up to 18 months following the first dose of treatment

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • Ashford Cancer Centre

    Kurralta Park, South Australia, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.